Active shortage

Dupixent 300 mg/2 mL injection

dupilumab · 300 mg/2 mL injection

Dupixent

Reported
22 February 2025
Expected resolution
31 October 2025
TGA reference
TGA-MSI-2025-038
Sponsor
Sanofi-Aventis Australia Pty Ltd

Reason for shortage

Global demand for dupilumab across atopic dermatitis, asthma and nasal polyps indications exceeding Sanofi production capacity.

What to do

  1. 1.
    Contact your pharmacistYour pharmacist can check current stock levels and advise on nearby pharmacies that may have supply. They can also assist with early dispensing to avoid running out.
  2. 2.
    Ask your doctor about alternativesYour GP or specialist can review whether a therapeutically equivalent alternative is appropriate for your situation. Never switch medicines without medical guidance.
  3. 3.
    Request early repeat if eligibleIf you have active repeats, your pharmacist may dispense an early repeat to build a short buffer supply while the shortage persists.
  4. 4.
    Check TGA for updatesThe TGA Medicine Shortage Information (MSI) database is updated regularly with expected resolution dates and approved substitutions.
  5. 5.
    Consider compounding if appropriateFor some medicines (particularly oral liquids or specific doses), a compounding pharmacist may be able to prepare an equivalent formulation.

Suggested alternatives

Same or related therapeutic class. Always discuss with your doctor or pharmacist before switching.

Official resources

MedWatch is for informational purposes only and does not constitute medical advice. Never stop or change your medicines without consulting your doctor or pharmacist. In an emergency, call 000. Medication queries: National Medicines Line 1300 633 424.